A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer

Alev Bakır Kayı; Benan Müsellim

Article Details

A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer

Authors:

Alev Bakır Kayı | Benan Müsellim

Publisher:

Marmara University

Main Topics:

Chest Diseases | Clinical Oncology

Journal:

Clinical and Experimental Health Sciences Vol.13 Issue 4, pp.764-768

Document Type:

Article

Publication Date:

12/2023

Document Language:

English

Document ID (Org No.):

2001298496

pISSN:

2459-1459

Keywords:

Abstract:

 Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival. Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included. Results: Out of 247 non-small cell lung cancer NSCLC cases analysis, 220 89 were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of diabetes and interstitial lung disease and 3.76 for diabetes and previously cancer. Existing comorbid indices had no significant effect on survival time p:0.684; 0.101; 0.273; 0.567, respectively. Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.

 Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival. Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included. Results: Out of 247 non-small cell lung cancer NSCLC cases analysis, 220 89 were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of diabetes and interstitial lung disease and 3.76 for diabetes and previously cancer. Existing comorbid indices had no significant effect on survival time p:0.684; 0.101; 0.273; 0.567, respectively. Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.

 Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival. Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included. Results: Out of 247 non-small cell lung cancer NSCLC cases analysis, 220 89 were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of diabetes and interstitial lung disease and 3.76 for diabetes and previously cancer. Existing comorbid indices had no significant effect on survival time p:0.684; 0.101; 0.273; 0.567, respectively. Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.

 Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival. Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included. Results: Out of 247 non-small cell lung cancer NSCLC cases analysis, 220 89 were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of diabetes and interstitial lung disease and 3.76 for diabetes and previously cancer. Existing comorbid indices had no significant effect on survival time p:0.684; 0.101; 0.273; 0.567, respectively. Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.

Article Details

A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer

Authors:

Alev Bakır Kayı | Benan Müsellim

Publisher:

Marmara University

Main Topics:

Chest Diseases | Clinical Oncology

Journal:

Clinical and Experimental Health Sciences Vol.13 Issue 4, pp.764-768

Document Type:

Article

Publication Date:

12/2023

Document Language:

English

Document ID (Org No.):

2001298496

pISSN:

2459-1459

Comorbidity index

comorbid disease

survival analysis

non-small cell lung cancer

Issues

Article Details

A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer

Authors: Alev Bakır Kayı | Benan Müsellim

Publisher: Marmara University

Main Topics: Chest Diseases | Clinical Oncology

Journal: Clinical and Experimental Health Sciences Vol.13 Issue 4, pp.764-768

Document Type: Article

Publication Date: 12/2023

Document Language: English

Document ID (Org No.): 2001298496

pISSN: 2459-1459

Comorbidity index

comorbid disease

survival analysis

non-small cell lung cancer

Issues

Authors:

Alev Bakır Kayı | Benan Müsellim

Publisher:

Marmara University

Main Topics:

Chest Diseases | Clinical Oncology

Journal:

Clinical and Experimental Health Sciences Vol.13 Issue 4, pp.764-768

Document Type:

Article

Publication Date:

12/2023

Document Language:

English

Document ID (Org No.):

2001298496

pISSN:

2459-1459